Cargando…

Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis

While overweight/obesity has become a major public health issue worldwide, any association between body mass index (BMI) and therapeutic response in neoadjuvant targeted therapy treated HER2 positive breast cancer patients remain unclear. The information from a total of four-hundred and ninety-one n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lili, Wu, Fan, Chen, Xiaobin, Chen, Yazhen, Deng, Lin, Cai, Qindong, Wu, Long, Guo, Wenhui, Chen, Minyan, Li, Yan, Zhang, Wenzhe, Jin, Xuan, Chen, Hanxi, Nie, Qian, Wu, Xiong, Lin, Yuxiang, Wang, Chuan, Fu, Fangmeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232579/ https://www.ncbi.nlm.nih.gov/pubmed/37258524 http://dx.doi.org/10.1038/s41523-023-00552-z

Ejemplares similares

Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Lin, Yuxiang, et al.
Publicado: (2022)

HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer
por: Chen, Xiaobin, et al.
Publicado: (2022)

YTHDF3 facilitates triple-negative breast cancer progression and metastasis by stabilizing ZEB1 mRNA in an m(6)A-dependent manner
por: Lin, Yuxiang, et al.
Publicado: (2022)

High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patients
por: Zhang, Wenzhe, et al.
Publicado: (2023)

Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer
por: Qiu, Lin, et al.
Publicado: (2016)

CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1
por: Lin, Yuxiang, et al.
Publicado: (2022)

Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy
por: Fu, Fangmeng, et al.
Publicado: (2022)

Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer
por: Zhang, Jiantang, et al.
Publicado: (2017)

Associations of Two Common Genetic Variants with Breast Cancer Risk in a Chinese Population: A Stratified Interaction Analysis
por: Lin, Yuxiang, et al.
Publicado: (2014)

Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients
por: Li, Yan, et al.
Publicado: (2022)

Genetic variants in long noncoding RNA H19 contribute to the risk of breast cancer in a southeast China Han population
por: Lin, Yuxiang, et al.
Publicado: (2017)

Transcriptional Expressions of CXCL9/10/12/13 as Prognosis Factors in Breast Cancer
por: Li, Yan, et al.
Publicado: (2020)

The precision relationships between eight GWAS-identified genetic variants and breast cancer in a Chinese population
por: Chen, Yazhen, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis
por: Wang, Chuan, et al.
Publicado: (2013)

Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis
por: Lin, Yuxiang, et al.
Publicado: (2020)

Polymorphisms of long non-coding RNA HOTAIR with breast cancer susceptibility and clinical outcomes for a southeast Chinese Han population
por: Lin, Yuxiang, et al.
Publicado: (2017)

Identifying Two Common Types of Breast Benign Diseases Based on Multiphoton Microscopy
por: Wu, Yan, et al.
Publicado: (2018)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Yu, Liuwen, et al.
Publicado: (2020)

LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
por: Guo, Wenhui, et al.
Publicado: (2021)

Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis
por: Wu, Di, et al.
Publicado: (2019)

Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer
por: Fu, Fangmeng, et al.
Publicado: (2018)

Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer
por: CHEN, WEICAI, et al.
Publicado: (2015)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
por: Chen, Hai-long, et al.
Publicado: (2023)

Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
por: Chen, Wei, et al.
Publicado: (2023)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis
por: Zhang, Jie, et al.
Publicado: (2021)

Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis
por: He, Lin, et al.
Publicado: (2019)

The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer
por: Lian, Weibin, et al.
Publicado: (2017)

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
por: Wang, Chaokun, et al.
Publicado: (2020)

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
por: Lin, Binwei, et al.
Publicado: (2023)

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
por: Wu, Wei, et al.
Publicado: (2021)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC
por: Zheng, Shuyue, et al.
Publicado: (2022)

Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer
por: Chen, Hao-ran, et al.
Publicado: (2017)

Association between the systemic immune-inflammation index and the efficacy of neoadjuvant chemotherapy, prognosis in HER2 positive breast cancer—a retrospective cohort study
por: Gu, Qiang, et al.
Publicado: (2023)

Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2023)

A nomogram prediction for the survival of patients with triple negative breast cancer
por: Lin, Yuxiang, et al.
Publicado: (2018)

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
por: Huang, Liang, et al.
Publicado: (2013)

Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery
por: Chen, Xiaobin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nd8784k496vcebksv7es7v6kub